DOI:

A rare publication with a unique message: the joint guidelines on the management of valvular heart disease by the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery

Davide Capodanno

This February issue is special because it contains only one article, but what an article! In fact, we are co-publishing the guidelines of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery on the management of valvular heart disease. We also have a timely editorial by Catherine Otto, first author of the joint American College of Cardiology and American Heart Association guidelines on the same topic, which illustrates the main similarities and differences of the two documents that come from either side of the Atlantic. On this occasion, I would like to thank the European Society of Cardiology for allowing the co-publication of this document in our Journal and the European Association of Percutaneous Cardiovascular Interventions, with its Board and Presidential trio, for their support in carrying out this request. I was part of the Task Force that drafted these guidelines, so I will refrain from personal comments on the contents. Social media, as always, has amplified the discussion around guidelines presented at the European Society of Cardiology Congress – which is positive for their broad dissemination and uptake. I have a feeling that the key principles of this document have been well-received, without divisions that go beyond the normal and fair scientific debate. After all, these are guidelines produced by the European Society of Cardiology together with the European Association for Cardio-Thoracic Surgery, which represents the most exemplary illustration of the Heart Team concept that is interwoven transversally throughout the document. Unsurprisingly, and in general, the guidelines methodology is debated. Catherine Otto, in her Editorial, mentions some aspects that can be improved upon with a view to creating an ever-better process. What I have learned as an author, however, is that the process is more solid than what I, myself, could have expected as a reader (and of course, you can decide to trust me or not). The process is intended to foster debate, representing different opinions and the involvement not only of the multidisciplinary components of the task force, but of countless reviewers as well. Contrary to more conspiratorial views, from what I can testify from my own personal experience, this is not a process that allows overly extreme or potentially biased opinions to take the lead. A methodological review is undertaken and strict rounds of votes with prespecified criteria are required before the several rounds of review process begin. I have seen some who are reluctant to reconcile their positions converge after long discussions in the interest of science and community service. I have no counterevidence to support this, but I would like to think that different people, using the same methodology and moving from the same extremes, would reach the same recommendations. That said, guidelines exist to inform readers about best practices regarding the treatment of certain conditions. It is up to us to read and interpret them for what they are: a practical guide that does not replace decisions based on science, experience and conscience, all in the best interests of our patients.

Supplementary data

To read the full content of this article, please download the PDF.

Volume 17 Number 14
Feb 4, 2022
Volume 17 Number 14
View full issue

Suggested by Cory

Editorial

10.4244/EIJ-E-24-00053 Nov 4, 2024
The future of sirolimus-coated balloon use in percutaneous coronary intervention
Yeh R and Lalani C
free

Original Research

10.4244/EIJ-D-23-00868 Nov 4, 2024
A randomised trial of sirolimus- versus paclitaxel-coated balloons for de novo coronary lesions
Scheller B et al

Original Research

10.4244/EIJ-D-24-00362 Nov 4, 2024
Natural history of a newly developed calcified nodule: incidence, predictors, and clinical outcomes
Sugizaki Y et al

Original Research

10.4244/EIJ-D-24-00779 Oct 27, 2024
Usefulness of FFR-CT to exclude haemodynamically significant lesions in high-risk NSTE-ACS
Meier D et al
free

EAPCI Column

Oct 21, 2024
EAPCI focus on the Online Coaching Programme
free

Editorial

10.4244/EIJ-E-24-00046 Oct 21, 2024
Phoenix rising: a credible signal for CABG from ISCHEMIA?
Bittl J
free
Trending articles
153.65

Clinical research

10.4244/EIJ-D-20-01125 Oct 20, 2021
An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation
Costa G et al
free
54.9

Expert review

10.4244/EIJ-D-21-01010 Jun 24, 2022
Device-related thrombus following left atrial appendage occlusion
Simard T et al
free
43.75

Clinical Research

10.4244/EIJ-D-21-01091 Aug 5, 2022
Lifetime management of patients with symptomatic severe aortic stenosis: a computed tomography simulation study
Medranda G et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved